Comments on the FDA’s Proposal to Exclude Bumetanide, Nicardipine Hydrochloride, and Vasopressin from the 503B Bulks List for Pharmacy Compounding by Outsourcing Facilities

View as PDF

Public Citizen strongly supports the Food and Drug Administration’s (FDA’s) proposal to exclude bumetanide, nicardipine hydrochloride, and vasopressin from the list of bulk drug substances for which there is a clinical need under Section 503B of the Federal Food, Drug, and Cosmetic Act for pharmacy compounding by outsourcing facilities. Each of the nominated bulk drug substances is a component of one or more FDA-approved drug products, and the nominators have failed to demonstrate that there is a clinical need for outsourcing facilities to compound drug products using the nominated bulk drug substances.

See Public Citizen’s other work on pharmacy compounding.